Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04968223
Other study ID # SPIRIT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 16, 2021
Est. completion date July 2024

Study information

Verified date November 2023
Source University of Oldenburg
Contact René Hurlemann, Prof.
Phone +49 (0)441 9615
Email rene.hurlemann@uni-oldenburg.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Recent studies have shown that certain biomarkers of schizophrenia could help to better assess the individual course of the disease and thus, contribute to more personalized treatment options. The aim of the SPIRIT study is to identify potential biomarkers for the prediction of disease-associated outcomes by investigating the neurobiological mechanisms of underlying schizophrenia-related dysfunctions.


Description:

Alterations in psychosocial functioning are evident from the prodromal phase of schizophrenia and play a crucial role in its chronic course. While recent studies have demonstrated the predictive validity of structural changes in the brain anatomy of patients with schizophrenia, there is a lack of studies assessing the predictive value of disease-associated alterations in the functional brain activity for symptom severity and psychosocial functioning in schizophrenia. In this longitudinal, observational study, 60 patients with schizophrenia and 40 healthy subjects without family history of psychotic illness will be recruited to investigate differences in behavioural, physiological, and neural correlates of social touch and interoceptive perception between participant groups. Participants' symptom severity and psychosocial functioning level will be examined by a wide range of behavioural, physiological, and neural methods. Potential biomarkers will be identified by estimating the predictive value of initially performed methods on follow-up re-examination of clinical and psychosocial outcomes. Neural readouts include structural and functional magnetic resonance imaging (fMRI) measurements. The fMRI tasks will probe the processing of social touch and interoceptive perception; additionally resting-state connectivity will be assessed. To further investigate pathological distortions of social touch and interoceptive perception, bodily touch allowance maps will be measured and participants will perform a heart-beat discrimination task. Psychometric questionnaires and semi-structured interviews will be used to capture symptom load and level of psychosocial functioning. Long-term effects will be assessed by online questionnaires and semi-structured interviews via phone call 3- and 6 months after initial assessments. The investigators hypothesize that differences in the neural response to social touch as well as in the neural patterns of interoceptive perception could serve as potential biomarkers for psychosocial deficits during the course of the illness. Furthermore, the inclusion of those biomarkers in predictive models could improve the prediction of disease progression and thus, contribute to personalized therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 2024
Est. primary completion date January 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participant is able to provide consent. - Diagnosis of schizophrenia or schizoaffective disorder according to DSM-V - Control group: No psychiatric or neurological illness. - Fluent in German. Exclusion Criteria: - The participant does not fulfill requirements for MRI measurements according to safety guidelines. - Acute suicidality. - Current substance dependence. - A history of head trauma or neurological illness.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Department of Psychiatry, University of Oldenburg Bad Zwischenahn

Sponsors (2)

Lead Sponsor Collaborator
University of Oldenburg Danilo Postin, M.Sc.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neural responses in a social touch task Participants will be measured with functional magnetic resonance imaging (fMRI) while they perceive different types of social and non-social touch One-time baseline assessment
Primary Behavioral responses in a social touch fMRI task Measured as behavioral ratings during the social touch fMRI task. During the social touch fMRI task, participants rate the comfort of the tactile stimuli on a visual analogue scale. One-time baseline assessment
Primary Neural responses in an interoception fMRI task Participants will be measured with functional magnetic resonance imaging (fMRI) while they perform an interoception task One-time baseline assessment
Primary Behavioral responses in an interoception fMRI task Measured by performance on the interoception task. During the interoception fMRI task, participants rate how intensely they perceived their heartbeat or their stomach on a visual analogue scale. One-time baseline assessment
Primary Changes in clinician-rated symptom severity between baseline and follow-ups Measured by half-structured interviews (e.g. Positive and Negative Syndrome Scale (PANSS); range: 30-210; higher scores indicating more severe symptoms) for disease-related symptoms Baseline, 3 and 6 months follow- up after initial baseline assessment
Primary Changes in self-reported symptom severity between baseline and follow-ups Measured by self-evaluation questionnaires (e.g. Self-assessment of Negative Symptoms (SNS); range 1-20; higher scores indicating more severe symptoms) for disease-related symptoms Baseline, 3 and 6 months follow- up after initial baseline assessment
Primary Changes in clinician-rated social-role functioning between baseline and follow-ups Measured by the clinician-rated the social-role functioning scale (range: 1-10; higher scores indicating higher functioning) Baseline, 3 and 6 months follow- up after initial baseline assessment
Primary Changes in self-reported social-role functioning levels between baseline and follow-ups Measured by the self-evaluation questionnaires for social-role functioning (e.g. Social Network Index (SNI); range 1-12; higher scores indicating higher functioning) Baseline, 3 and 6 months follow-up after initial baseline assessment
Secondary Bodily maps of social touch Measured as performance on a bodily maps computer task One-time baseline assessment
Secondary Attitude towards social touch Measured by the self-evaluation questionnaire for social touch tolerance (e.g. Social Touch Questionnaire; range 0-4; higher scores indicating higher touch tolerance) One-time baseline assessment
Secondary Interoceptive accuracy Measured as performance on a heartbeat discrimination task One-time baseline assessment
Secondary Interoceptive awareness Measured by a self-evaluation questionnaire for interoceptive awareness (e.g. Multidimensional Assessment of Interoceptive Awareness (MAIA); range 0-5; higher scores indicating higher interoceptive awareness) One-time baseline assessment
Secondary Blood parameter Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics One-time baseline assessment
Secondary Urine parameter Measured by schizophrenia related, Nuclear Magnetic Resonance spectroscopy (NMR) based metabolomics One-time baseline assessment
Secondary Neural activity at resting state fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open. One-time baseline assessment
Secondary Structural connectivity measure fMRI will be performed to measure BOLD-signal while participants lay in the MRI-scanner with eyes open. One-time baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A